Meeting
2022 ASCO Annual Meeting
Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).
Authors
Xue Meng
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
Xue Meng , Anping Zheng , Jun Wang , Jianhua Wang , Guang Li , Jun Zhu , Hu Ma , Xiaodong Zhu , Anhui Shi , Chunhua Dai , Senxiang Yan , Buhai Wang , Zhongyu Qu , Chun Han , Xindong Sun , Ming Ye , Ruitai Fan , Ni yazi Huerxidan , Xiaohong Wang , Jinming Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
02409186
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4016)
DOI
10.1200/JCO.2022.40.16_suppl.4016
Abstract #
4016
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.
First Author: Karyn A. Goodman
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.
First Author: Luhua Wang
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).
First Author: Shom Goel
Poster
2021 Gastrointestinal Cancers Symposium
CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jin Li